Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study

D. Griffith (Tyler, United States of America), R. Thomson (Brisbane, Australia), D. Addrizzo-Harris (New York, United States of America), S. Field (Calgary, Canada), J. Van Ingen (Nijmegen, Netherlands), C. Coulter (Brisbane, Australia), K. Mange (Bridgewater, United States of America), J. Nezamis (Bridgewater, United States of America), K. Winthrop (Portland, United States of America)

Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections
Session: Advances in bronchiectasis and non-TB mycobacterial infections
Session type: Oral Presentation
Number: 4951
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Griffith (Tyler, United States of America), R. Thomson (Brisbane, Australia), D. Addrizzo-Harris (New York, United States of America), S. Field (Calgary, Canada), J. Van Ingen (Nijmegen, Netherlands), C. Coulter (Brisbane, Australia), K. Mange (Bridgewater, United States of America), J. Nezamis (Bridgewater, United States of America), K. Winthrop (Portland, United States of America). Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study. 4951

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: